Jiangsu Jibeier Pharmaceutical (688566) Q3 2026 earnings summary

Executive summary

• Q3 revenue rose 14.29% YoY to RMB 285.2m; attributable net income increased 61.13% to RMB 76.7m, while 9M reported net income fell 10.66% YoY.

• 9M adjusted net income increased 14.15% YoY to RMB 175.2m; operating cash flow rose 33.65% to RMB 224.0m.

• Q3 financial statements were unaudited.

Financial highlights

• 9M revenue was RMB 774.7m, up 9.98% YoY; total profit was RMB 200.6m, down 11.88%.

• 9M attributable net income was RMB 175.9m, down 10.66% YoY; adjusted attributable net income was RMB 175.2m, up 14.15%.

• 9M operating costs totaled RMB 570.3m versus RMB 526.6m; selling expenses were RMB 382.9m versus RMB 363.6m.

Key financial ratios and metrics

• Q3 basic and diluted EPS were RMB 0.38, each up 58.33% YoY; 9M EPS was RMB 0.88, down 11.11%.

• Weighted-average ROE was 3.02% for Q3, up 1.01 percentage points; 9M ROE was 7.00%, down 1.46 points.

• 9M R&D expense was RMB 44.1m, down 15.70% YoY; R&D was 5.69% of revenue, down 1.74 percentage points.

• Total assets were RMB 2.882bn at quarter-end, up 6.07% from year-end; parent-attributable equity was RMB 2.550bn, up 4.94%.